Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY PATENT APPLICATION **TRANSMITTAL**

001107.00229 Attorney Docket No. First Inventor NOGEE et al.

(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))

SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE Express Mail Label No.

	- V			
APPLICATION ELEMENTS	Assistant Commissioner for Patents  Box Patent Application Washington, DC 20231			
See MPEP chapter 600 concerning utility patent application contents.				
1. See Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)  Applicant claims small entity status. See 37 CFR 1.27.  Specification [Total Pages 34] (preferred arrangement set forth below) - Descriptive title of the Invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a. ☐ Computer Readable Form (CRF)  b. Specification Sequence Listing on: i. ☐ CD-ROM or CD-R (2 copies); or ii. ☐ paper  c. ☐ Statements verifying identity of above copies  ACCOMPANYING APPLICATIONS PARTS  9. ☐ Assignment Papers (cover sheet & document(s))  10. ☐ 37 C.F.R.§3.73(b) Statement ☐ Power of (when there is an assignee) Attorney  11. ☐ English Translation Document (if applicable)			
4. Drawing(s) (35 U.S.C.113) [Total Sheets 4 ] 5. Oath or Declaration [Total Pages ] a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63 (d))  (for a continuation/divisional with Box 18 completed)	12. Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations  13. Preliminary Amendment  14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15. Certified Copy of Priority Document(s)			
<ul> <li>i. ☐ DELETION OF INVENTOR(S)         Signed statement attached deleting inventor(s)         named in the prior application, see 37 CFR         1.63(d)(2) and 1.33(b).</li> <li>6. ☒ Application Data Sheet. See 37 CFR 1.76</li> </ul>	(if foreign priority is claimed)  16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.  17. Other:			
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:				
Continuation □ Divisional □ Continuation-in-part (CIP) of prior application No:/  Prior application information: Examiner □ Group / Art Unit: □ Group / Art Unit: □ For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.				
	NDENCE ADDRESS			
22907				
Name				
Address				
City State	Zip Code			
Country Telephone	Fax			
Name (Print/Type) Lisa M. Hemmendinger	Registration No. (Attorney/Agent) 42,653			
Signature Lya M. Henculadia of	Date February 14, 2002			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of		)	
NOGE	E et al.	)	Group Art Unit: unassigned
Serial 1	No. T.B.A.	) )	Examiner: unassigned
Filed:	even herewith	)	Atty. Dkt. No. 001107.00229
For:	SINGLE NUCLEOTIDE POLYMORPHISMS INTERSTITIAL LUNG DISEASE	As	SOCIATED WITH

## TRANSMITTAL OF COMPUTER READABLE FORM OF SEQUENCE LISTING

Assistant Director of Patents Washington, D.C. 20231

Sir:

Applicants herewith submit a computer readable form of the sequence listing included in the application referenced above. I believe the contents of the computer readable form and the paper copy of the sequence listing included in the application as filed are identical.

Respectfully submitted,

Date: 2-14-02

By: Lisa M. Hemmendinger Registration No. 42,653

Banner & Witcoff, Ltd. 1001 G Street, N.W., Eleventh Floor Washington, D.C. 20001-4597 (202) 508-9100